Synthesis of Critical Chemical Intermediate for Drug Confirmed
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer, which the Company has licensed from the University of Texas at Austin.
Pancreatic cancer is the 4th leading cause of cancer deaths in the US and, partly because most cases are diagnosed at an advanced stage, the 5-year overall survival rate for those cases has remained only around 3%. See Sci Rep 10, 7048 (2020). The Company is developing its drug product as an orally administered second-line treatment to target advanced pancreatic cancer.
The Company confirmed this week the successful synthesis of a critical intermediate compound for DHA-dFdC. Purification and isolation of this key intermediate were also completed and verified. The Company is also in the process of optimizing the SLN delivery vehicle with respect to particle size and stability.
In addition, the Company recently expanded upon its agreement with Parimer Scientific to immediately begin manufacturing activities including the following:
Developing analytical methods for both raw materials and final drug product,
Producing an optimized process for batch scale-up of the drug,
Producing and delivering 20,000 mg of final drug product to be used in toxicology studies,
Performing initial short-term and long-term stability testing in the selected bulk container closure using ICH Q1A(R2) Stability Testing of New Drug Substances and Products,
Creating a drug substance reference standard, and
Establishing drug purity per the relevant FDA standards.
Under the expanded agreement, the final drug product will be manufactured using at minimum GLP practices per 21 CFR 58 and following the recommendations in the FDA's ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.
Dr. Richard T. Pace, Principal Scientist at Parimer Scientific commented, "We are very gratified to have confirmed isolation of the crucial chemical intermediate for this drug. These results strongly indicate that developing a scalable process for drug manufacture will be achievable."
Anthony Hayes, CEO of AIkido stated, "These are the results we have been hoping for and they greatly increase my optimism about the scalability of this product. We plan to rapidly develop the process of drug incorporation into the SLN delivery particles and start preliminary biological testing, which should begin this quarter."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-provides-update-on-its-next-generation-chemotherapeutic-treatment-dha-dfdc-301162021.html
SOURCE AIkido Pharma Inc.
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 3/5/2021
Views: 932
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 3/3/2021
Views: 914
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 3/1/2021
Views: 942
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 3/1/2021
Views: 1352
Meet Aikido Pharma Inc’s Board of Directors
Released On: 2/28/2021
Views: 962
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 2/23/2021
Views: 982
Artificial Intelligence Is Optimizing Drug Development
Released On: 2/22/2021
Views: 1010
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 2/20/2021
Views: 892
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 2/19/2021
Views: 1048
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 2/16/2021
Views: 1141
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 2/16/2021
Views: 1094
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 2/16/2021
Views: 1235
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 2/15/2021
Views: 893
Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19
Released On: 2/10/2021
Views: 803
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 2/9/2021
Views: 1404
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 2/5/2021
Views: 979
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 2/3/2021
Views: 1855
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 2/3/2021
Views: 1078